Image Source: Zacks Investment Research Quest Diagnostics (DGX) entered into a definitive agreement with Allina Health to acquire its select laboratory assets. The transaction is expected to be closed in the third quarter of 2024, subject to customary regulatory reviews. More on the News The deal is expected to be strategically aligned as Quest Diagnostics and Allina Health share common interests like helping a range of communities benefit from quality, innovative, and affordable laboratory services. Per a ...

SECAUCUS, N.J., June 27, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's report provides information on the company's corporate responsibility strategy and environmental, social, and governance (ESG) priorities, which align with The Quest Way, the company's approach to achieving its goals. The Quest Way is comprised of the company's Purpose, strategy and culture. Quest Diagnostics Releases 2 ...

SECAUCUS, N.J. and MINNEAPOLIS, June 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and Allina Health, a leading, non-profit health care system, today announced a definitive agreement for Quest to acquire select laboratory assets from Allina Health, with the goal to improve access to and the affordability of innovative laboratory services across Minnesota and western Wisconsin. "Our transaction with Allina Health will extend access to Quest's e ...

Hims & Hers Heath stock has surged 165.9% in the past year. Estimates for the company's earnings have moved upward from 18 cents to 19 cents for 2024 and from 33 cents to 35 cents for 2025 in the past seven days. Additionally, Quest Diagnostics is making headway with several promising opportunities in its robust M&A pipeline, with the recent acquisition of Lenco contributing to its first-quarter growth. Base volume growth within Hospital Lab Services will continue, courtesy of the strength in professional l ...

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call. About Quest Diagnostics Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion o ...

The transaction builds on Quest Diagnostics' leadership in oncology and subspecialized pathology services. It will support PathAI's strategy to amplify its investments in AI technology and expand its software and algorithm business. AI in pathology offers numerous advantages, including improved accuracy, increased efficiency and enhanced patient care. Furthermore, the growing demand for misdiagnosis, funding initiatives for improving patient care quality and increasing emphasis on cost control and efficienc ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/ -- A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in J ...

Quest Diagnostics Q1 Earnings Surpass, Margins Crash Quest Diagnostics Incorporated's first-quarter 2024 adjusted earnings per share of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure. Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter's adjusted figures. GAAP ...

SECAUCUS, N.J., May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members. Rob CarterRob Carter Mr. Carter, 64, is Executive Vice President and Chief Information Officer at FedEx Corporation, where he is responsible for setting the technology direction of the F ...

SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024. SOURCE Quest Diagnostics About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from ...